PRAX Praxis Precision Medicines
- 43.830
- -0.420-0.95%
- 42.950
- -0.880-2.01%
Praxis Precision Medicines News
Daily options tracking | Nvidia's market cap has risen to the second highest globally, with multiple call options surging 7 times; Gamestop rose more than 19% overnight, with multiple call options being snapped up.
Meta's overnight options trading volume was 460,000 contracts, an increase of over 210% compared to the previous day, with the call-to-put ratio rising from 56% to 68%. Calls with a strike price of $490 that expire on Friday were sought after, with a trading volume of 33,000 contracts and an open interest of nearly 4,000 contracts. It is noteworthy that multiple call options with the same expiration date earned 7 times the option premium.
Express News | Praxis Precision Medicines announced the issuance of incentive allowances in accordance with NASDAQ Rule 5635(c)(4).
Express News | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate
Praxis Precision Medicines Inc: Jefferies Raises Price Target from $128 to $141
Praxis Precision Medicines Inc: Jefferies Raises Price Target from $128 to $141
Express News | Praxis Precision Medicines Inc : Jefferies Raises Target Price to $141 From $128
Praxis Precision Medicines (NASDAQ:PRAX): A Wild Rollercoaster Ride
Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), Corbus Pharmaceuticals (CRBP)
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous
Praxis Precision Med Price Target Maintained With a $150.00/Share by Truist Securities
Praxis Precision Med Price Target Maintained With a $150.00/Share by Truist Securities
Truist Securities Maintains Buy on Praxis Precision Medicine, Maintains $150 Price Target
Truist Securities analyst Joon Lee maintains Praxis Precision Medicine with a Buy and maintains $150 price target.
Buy Rating Backed by Robust Pipeline and Market Opportunity for Praxis Precision Medicines
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)
Praxis Precision Medicines Shares Drop 5% After 1Q Results Miss Expectations
By Zaeem Shoaib Praxis Precision Medicines shares dropped after the company reported a loss for the first quarter that was wider than analyst expectations Shares were down 5.7% to $46.01. The stock
Praxis Precision Medicines | 10-Q: Quarterly report
Praxis Precision Medicine Says Cash And Investments Of $451.2M As Of April 30, 2024 Extends Runway Into 2027
Praxis Precision Medicine Says Cash And Investments Of $451.2M As Of April 30, 2024 Extends Runway Into 2027
Praxis Precision Medicines Advances Precision Therapies for CNS Disorders, Anticipates Key Milestones in Seizure and Pediatric Epilepsy Treatment
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders cha
Analysis
Price Target
No Data
